SCHEMBL13328898

SCHEMBL13328898

CCOC(=O)N1CCc2nc(C)n(C(c3ccccc3)c3ccccc3)c(=O)c2C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.45
GAA P10253 2/20 0.44
MTHFD2 P13995 1/20 0.42
WEE1 P30291 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.41
ALDH1A1 P00352 5/20 0.41
KDM4E B2RXH2 2/20 0.41
TP53 P04637 3/20 0.41
LMNA P02545 3/20 0.41
PABPC1 P11940 1/20 0.41
ATM Q13315 1/20 0.41
MAPT P10636 3/20 0.39
MEN1 O00255 2/20 0.39
MAPK1 P28482 2/20 0.39
KMT2A Q03164 2/20 0.39
HPGD P15428 1/20 0.39
HSD17B10 Q99714 1/20 0.39
HTT P42858 1/20 0.38
RAB9A P51151 1/20 0.38
MDM2 Q00987 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13328901 0.94 PPARG (0.41) TSHRGAAMTHFD2WEE1SMN1; SMN2
SCHEMBL13328904 0.93 MTHFD2 (0.39) TSHRGAAMTHFD2WEE1SMN1; SMN2
SCHEMBL13250035 0.93 TSHR (0.48) TSHRGAASMN1; SMN2ALDH1A1KDM4E
SCHEMBL13328919 0.92 KDR (0.47)
SCHEMBL13328906 0.92 PPARG (0.42) TSHRGAAMTHFD2WEE1SMN1; SMN2
SCHEMBL13249786 0.92 TSHR (0.45) TSHRGAAWEE1SMN1; SMN2ALDH1A1
SCHEMBL13328916 0.92 P2RY12 (0.39) TSHRGAAMTHFD2WEE1SMN1; SMN2
SCHEMBL13328912 0.91 MTHFD2 (0.41) TSHRGAAMTHFD2WEE1SMN1; SMN2
SCHEMBL13328900 0.91 MTHFD2 (0.39) TSHRGAAMTHFD2WEE1SMN1; SMN2
SCHEMBL13328897 0.91 CCR5 (0.44) TSHRMTHFD2CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8318751-B2 Pyrimidinone derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2012-11-27 US disclosed
US-8318751-B2 Pyrimidinone derivatives and methods of use thereof MERCK SHARP & DOHME CORP. (US) 2012-11-27 US disclosed
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF MERCK SHARP & DOHME CORP. 2010-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113487-A1 PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF GPR119, GPR180, GPR17 TSHR 1894/4885GAA 913/4885MTHFD2 1017/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.